Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Bitcoin USD

    63,796.97
    -813.90 (-1.26%)
     

  • CMC Crypto 200

    1,328.60
    -67.94 (-4.87%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • Dow

    38,239.66
    +153.86 (+0.40%)
     

  • Nasdaq

    15,927.90
    +316.14 (+2.03%)
     

  • Gold

    2,349.60
    +7.10 (+0.30%)
     

  • Crude Oil

    83.66
    +0.09 (+0.11%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

After Announcing Cuts, Is CVS Still a Safe Stock?

Alex Carchidi, The Motley Fool
·4-min read
After Announcing Cuts, Is CVS Still a Safe Stock?

On Sunday, CVS Health (NYSE: CVS) revealed that it would be shuttering its clinical trial services segment by the end of 2024, according to reporting from biopharma industry trade publication Endpoints News. The pharmacy and health insurance giant began its foray into this space in 2021, and originally used its access to consumers to aid drugmakers in recruiting participants for COVID-19 vaccine trials and other coronavirus-related clinical investigations, but apparently, management doesn't feel that the business is contributing significantly to the company's prospects. Does this mean that CVS stock isn't as safe as shareholders have believed?

Continue reading